Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, suppress cell proliferation and induce apoptosis in various cancer cell lines. However, the eŠects of statins in head and neck carcinoma have not been reported. In this study, we investigated the mechanism by which ‰uvastatin induces apoptosis in HSC-3 cells. An increase in caspase-3 activity was observed. The apoptosis induced by ‰uvastatin was inhibited by the addition of geranylgeranyl pyrophosphate (GGPP) to the cell culture. When we examined the survival signals at the time of apoptotic induction, we also found that ‰uvastatin had caused a remarkable decrease in the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. Moreover, we also found that U0126, a MEK1/2 inhibitor, induces apoptosis in HSC-3 cells. These results suggested that ‰uvastatin induces apoptosis by inhibiting GGPP biosynthesis and consequently decreasing the level of phosphorylated ERK1/2. The results of this study also indicate that ‰uvastatin may be used as an anticancer agent for tongue carcinoma.
(B) HSC-3 cells were treated with 2.5 mM ‰uvastatin for 24, 48, and 72 hr. Whole-cell lysates were generated and immunoblotted with antibodies against phosphorylated ERK1/2 (phospho-ERK1/2), phosphorylated Akt (phospho-Akt), ERK1/2, and Akt. After administration of 2.5 mM ‰uvastatin, the levels of phosphorylated ERK1/2 were lower than those in control cells. (C) HSC-3 cells were pretreated with 1 mM MVA, 10 mM FPP, or 10 mM GGPP for 4 hr and then treated with 2.5 mM ‰uvastatin for 72 hr. Whole-cell lysates were generated and immunoblotted with antibodies against phosphorylated ERK1/2 (phospho-ERK1/2), and ERK1/2. 
